查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1610204

癌细胞病毒治疗市场：按病毒类型、应用和最终用途 - 2025-2030 年全球预测

Oncolytic Virus Therapies Market by Virus Type (Genetically Engineered Oncolytic Viruses, Oncolytic Wild-type Viruses), Application (Breast Cancer, Lung Cancer, Melanoma), End Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年癌细胞病毒治疗市值为1.1753亿美元，预计2024年将达到1.325亿美元，复合年增长率为15.45%，到2030年将达到3.213亿美元。

癌细胞病毒疗法是癌症治疗的一个有前景的前沿领域，涉及使用基因工程或天然存在的病毒来选择性地感染和破坏癌细胞，同时不伤害正常组织。癌症盛行率的上升和传统治疗方法的局限性凸显了对此类创新方法的需求。这些治疗方法已应用于治疗多种癌症，包括黑色素瘤、神经胶母细胞瘤和胰腺癌，并且主要用于医疗机构和实验室。该市场受到几个关键成长要素的影响，例如基因工程的进步、癌症研究投资的增加以及对标靶治疗的需求不断增长。该市场的一个重要机会在于开拓联合治疗，利用溶瘤病毒与免疫疗法和化疗的协同效应来提高疗效并扩大治疗范围。

主要市场统计
基准年[2023] 11753万美元
预计年份 [2024] 1.325 亿美元
预测年份 [2030] 3.213 亿美元
复合年增长率（%） 15.45%

影响成长的主要限制包括严格的临床试验要求和潜在的安全问题导致的监管障碍，以及病毒递送和标靶化肿瘤的挑战。此外，高昂的研发成本和强大参与者的竞争格局也带来了重大挑战。然而，增强病毒选择性和效力、开发新的递送方法以及探索新病毒株等创新领域为业务成长提供了重大机会。市场的性质目前正处于起步阶段，但正在迅速发展阶段，公共和私营部门都进行了大量投资。该研究向相关人员提出的建议包括促进与学术和生物技术机构的合作，以推进研究并保持竞争优势；扩大全球合作伙伴关係以加强市场渗透；以及重点关注针对患者群体的个性化医疗方法，以最大限度地提高临床和市场成功。

市场动态：快速发展的癌细胞病毒治疗市场揭示的关键市场洞察

供需的动态交互作用正在改变癌细胞病毒治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 世界人口癌症发生率上升
    • 传播免疫疗法的意识计划
  • 市场限制因素
    • 与癌细胞病毒疗法相关的风险和併发症
  • 市场机会
    • 持续研发开发先进的癌细胞病毒疗法
    • 癌细胞病毒疗法作为精准医学策略的兴起
  • 市场挑战
    • 围绕 Oncolyte 病毒治疗的复杂法律规范

波特五力：开拓癌细胞病毒治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解癌细胞病毒治疗市场的外部影响

外部宏观环境因素在塑造癌细胞病毒治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解癌细胞病毒治疗市场的竞争格局

对癌细胞病毒治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV定位矩阵癌细胞病毒治疗市场供应商绩效评估

FPNV 定位矩阵是评估癌细胞病毒治疗市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了癌细胞病毒治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对癌细胞病毒治疗市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 世界人口癌症发生率上升
      • 促进免疫疗法的意识计划
    • 抑制因素
      • 与癌细胞病毒疗法相关的风险和併发症
    • 机会
      • 持续研发开发先进的癌细胞病毒疗法
      • 癌细胞病毒疗法作为精准医学策略的兴起
    • 任务
      • 围绕溶瘤病毒治疗的复杂法规结构
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章按病毒类型分類的癌细胞病毒治疗市场

  • 基因工程溶瘤病毒
  • 溶瘤野生型病毒

第七章癌细胞病毒治疗市场：依应用分类

  • 乳癌
  • 肺癌
  • 恶性黑色素瘤
  • 卵巢癌
  • 摄护腺癌

第八章癌细胞病毒治疗市场：依最终用途

  • 癌症研究组织
  • 医院
  • 专科诊所

第九章美洲癌细胞病毒治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太癌细胞病毒治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲的癌细胞病毒治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Amunbio Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • BioInvent International AB
  • Boehringer Ingelheim International GmbH
  • Calidi Biotherapeutics, Inc.
  • Candel Therapeutics
  • Daiichi Sankyo Company Ltd.
  • Elicera Therapeutics AB
  • EpicentRx, Inc.
  • Genelux Corporation
  • Hookipa Pharma Inc.
  • Imvaq Therapeutics
  • Istari Oncology, Inc.
  • Johnson & Johnson Services, Inc.
  • Lokon Pharma AB
  • Merck & Co., Inc.
  • Orgenesis Inc.
  • Pfizer, Inc.
  • Protheragen Inc.
  • Seneca Therapeutics, Inc.
  • Takara Bio Inc.
  • TILT Biotherapeutics
  • Treovir LLC
  • Wuhan Binhui Biotechnology Co Ltd
Product Code: MRR-007C484E5E64

The Oncolytic Virus Therapies Market was valued at USD 117.53 million in 2023, expected to reach USD 132.50 million in 2024, and is projected to grow at a CAGR of 15.45%, to USD 321.30 million by 2030.

Oncolytic virus therapies represent a promising frontier in cancer treatment, focusing on the use of genetically engineered or naturally occurring viruses to selectively infect and destroy cancer cells while sparing normal tissues. The rising prevalence of cancer, coupled with the limitations of traditional therapies, underscores the necessity for such innovative approaches. These therapies are applied in the treatment of a variety of cancers, including melanoma, glioblastoma, and pancreatic cancer, among others, and are primarily used by healthcare institutions and research laboratories. The market is influenced by several key growth factors, including advances in genetic engineering, increasing investment in cancer research, and the growing demand for targeted therapies. A major opportunity within this market lies in the development of combination therapies, which leverage the synergistic effects of oncolytic viruses with immunotherapies or chemotherapies, thereby enhancing efficacy and broadening therapeutic scope.

KEY MARKET STATISTICS
Base Year [2023] USD 117.53 million
Estimated Year [2024] USD 132.50 million
Forecast Year [2030] USD 321.30 million
CAGR (%) 15.45%

The major limitations impacting growth include regulatory hurdles due to stringent clinical trial requirements and potential safety concerns, as well as challenges related to the delivery and targeting of viruses to tumors. Additionally, high R&D costs and a competitive landscape with strong players pose significant challenges. Nonetheless, areas of innovation like the enhancement of virus selectivity and potency, the development of new delivery methods, and exploration of novel virus strains present vast opportunities for business growth. As for market nature, it is currently in a nascent but rapidly evolving stage with significant investments from both public and private sectors. Recommendations for stakeholders include fostering collaborations with academic and biotech institutions to drive research and maintain competitive advantage, expanding partnerships globally to enhance market penetration, and focusing on personalized medicine approaches to cater to specific patient subsets, thus maximizing clinical and market success.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oncolytic Virus Therapies Market

The Oncolytic Virus Therapies Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising incidence of cancer among the global population
    • Awareness program to promote immunotherapy
  • Market Restraints
    • Risk and complication associated with oncolytic virus therapies
  • Market Opportunities
    • Ongoing R&D to develop advanced oncolytic virus therapies
    • Rise of oncolytic virus therapies as a precision medicine strategy
  • Market Challenges
    • Complex regulatory framework surrounding oncolytic virus therapy

Porter's Five Forces: A Strategic Tool for Navigating the Oncolytic Virus Therapies Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oncolytic Virus Therapies Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oncolytic Virus Therapies Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oncolytic Virus Therapies Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oncolytic Virus Therapies Market

A detailed market share analysis in the Oncolytic Virus Therapies Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oncolytic Virus Therapies Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oncolytic Virus Therapies Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oncolytic Virus Therapies Market

A strategic analysis of the Oncolytic Virus Therapies Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oncolytic Virus Therapies Market, highlighting leading vendors and their innovative profiles. These include Amunbio Inc., Astellas Pharma Inc., AstraZeneca PLC, BioInvent International AB, Boehringer Ingelheim International GmbH, Calidi Biotherapeutics, Inc., Candel Therapeutics, Daiichi Sankyo Company Ltd., Elicera Therapeutics AB, EpicentRx, Inc., Genelux Corporation, Hookipa Pharma Inc., Imvaq Therapeutics, Istari Oncology, Inc., Johnson & Johnson Services, Inc., Lokon Pharma AB, Merck & Co., Inc., Orgenesis Inc., Pfizer, Inc., Protheragen Inc., Seneca Therapeutics, Inc., Takara Bio Inc., TILT Biotherapeutics, Treovir LLC, and Wuhan Binhui Biotechnology Co Ltd.

Market Segmentation & Coverage

This research report categorizes the Oncolytic Virus Therapies Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Virus Type, market is studied across Genetically Engineered Oncolytic Viruses and Oncolytic Wild-type Viruses.
  • Based on Application, market is studied across Breast Cancer, Lung Cancer, Melanoma, Ovarian Cancer, and Prostate Cancer.
  • Based on End Use, market is studied across Cancer Research Institutes, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising incidence of cancer among the global population
      • 5.1.1.2. Awareness program to promote immunotherapy
    • 5.1.2. Restraints
      • 5.1.2.1. Risk and complication associated with oncolytic virus therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D to develop advanced oncolytic virus therapies
      • 5.1.3.2. Rise of oncolytic virus therapies as a precision medicine strategy
    • 5.1.4. Challenges
      • 5.1.4.1. Complex regulatory framework surrounding oncolytic virus therapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Oncolytic Virus Therapies Market, by Virus Type

  • 6.1. Introduction
  • 6.2. Genetically Engineered Oncolytic Viruses
  • 6.3. Oncolytic Wild-type Viruses

7. Oncolytic Virus Therapies Market, by Application

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Lung Cancer
  • 7.4. Melanoma
  • 7.5. Ovarian Cancer
  • 7.6. Prostate Cancer

8. Oncolytic Virus Therapies Market, by End Use

  • 8.1. Introduction
  • 8.2. Cancer Research Institutes
  • 8.3. Hospitals
  • 8.4. Specialty Clinics

9. Americas Oncolytic Virus Therapies Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Oncolytic Virus Therapies Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Oncolytic Virus Therapies Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amunbio Inc.
  • 2. Astellas Pharma Inc.
  • 3. AstraZeneca PLC
  • 4. BioInvent International AB
  • 5. Boehringer Ingelheim International GmbH
  • 6. Calidi Biotherapeutics, Inc.
  • 7. Candel Therapeutics
  • 8. Daiichi Sankyo Company Ltd.
  • 9. Elicera Therapeutics AB
  • 10. EpicentRx, Inc.
  • 11. Genelux Corporation
  • 12. Hookipa Pharma Inc.
  • 13. Imvaq Therapeutics
  • 14. Istari Oncology, Inc.
  • 15. Johnson & Johnson Services, Inc.
  • 16. Lokon Pharma AB
  • 17. Merck & Co., Inc.
  • 18. Orgenesis Inc.
  • 19. Pfizer, Inc.
  • 20. Protheragen Inc.
  • 21. Seneca Therapeutics, Inc.
  • 22. Takara Bio Inc.
  • 23. TILT Biotherapeutics
  • 24. Treovir LLC
  • 25. Wuhan Binhui Biotechnology Co Ltd

LIST OF FIGURES

  • FIGURE 1. ONCOLYTIC VIRUS THERAPIES MARKET RESEARCH PROCESS
  • FIGURE 2. ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ONCOLYTIC VIRUS THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. ONCOLYTIC VIRUS THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ONCOLYTIC VIRUS THERAPIES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ONCOLYTIC VIRUS THERAPIES MARKET DYNAMICS
  • TABLE 7. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY GENETICALLY ENGINEERED ONCOLYTIC VIRUSES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY ONCOLYTIC WILD-TYPE VIRUSES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 27. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 30. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 33. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 36. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 47. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 50. INDIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 53. INDONESIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 56. JAPAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 59. MALAYSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 62. PHILIPPINES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 65. SINGAPORE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 68. SOUTH KOREA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 71. TAIWAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 74. THAILAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 77. VIETNAM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 84. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 87. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 90. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 93. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 96. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 99. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 102. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 105. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 108. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 111. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 114. POLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 117. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 120. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 123. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 129. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 132. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 135. SWITZERLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 138. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY VIRUS TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM ONCOLYTIC VIRUS THERAPIES MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 147. ONCOLYTIC VIRUS THERAPIES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 148. ONCOLYTIC VIRUS THERAPIES MARKET, FPNV POSITIONING MATRIX, 2023